For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions

These studies clinically demonstrate that Tirzepatide not only suppresses appetite but also increases fat oxidation (the bodys ability to burn fat for energy)
Read More Book a free consultation with Crystal an honest conversation about your goals and the right plan for you.
Peptide therapy can stimulate collagen production, improve the skin's elasticity, and diminish wrinkles
We understand that weight loss is personal, and our team is here to support you from the first dose to your long-term success
Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial contamination and allows multi-use access for up to 28 days making it more practical and cost-effective for researchers reconstituting multiple compounds